SNG Share PerformanceMore
|52 week high||38.00 25/04/16|
|52 week low||18.08 21/10/16|
|52 week change||-10.25 (-35.34%)|
|4 week volume||4,224,131 27/09/16|
Media for (SNG)
Latest News« previous» nextMore
13/10/2016 - 10:44 RNS
RNS Number: 4682M Synairgen plc 13 October 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Synairgen plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or dis...
12/10/2016 - 09:04 StockMarketWire
Synairgen (SNG) has confirmed that AstraZeneca has decided to stop the Phase IIa trial for AZD9412 based on an interim ...
12/10/2016 - 08:44 StockMarketWire
London stocks shrugged offer an early sour start to be cautiously ahead, with both the blue-chip and mid-cap indices risin...
12/10/2016 - 07:00 RNS
RNS Number: 2831M Synairgen plc 12 October 2016 Press release Synairgen plc ('Synairgen' or the 'Company') AZD9412 Clinical Trial Update ~ AstraZeneca to focus on key secondary endpoints with results expected in Q1 2017 ~ Southampton, UK - 12 October 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announced today t...
22/09/2016 - 13:30 StockMarketWire
N+1 Singer today reaffirms its buy investment rating on Synairgen PLC (LON:SNG) and cut its price target to 46p (from 4...
22/09/2016 - 09:50 StockMarketWire
Synairgen has widened its H1 pretax loss to 1.7m, from a year-earlier loss of 1.0m. Revenue was nil, from 25,000. "We are ve...
22/09/2016 - 07:00 RNS
RNS Number: 5051K Synairgen plc 22 September 2016 Press release Synairgen plc ('Synairgen' or the 'Company') Interim results for the six months ended 30 June 2016 ~ Clinical development of AZD9412 with AstraZeneca on track and Pharmaxis collaboration progressing towards the clinic ~ Southampton, UK - 22 September 2016: Synairgen plc (LSE: SNG), the respir...
08/09/2016 - 07:00 RNS
RNS Number: 2364J Synairgen plc 08 September 2016 PRESS RELEASE 8 September 2016 SYNAIRGEN PLC ("Synairgen" or "the Company") Notice of Interim Results Southampton, UK, 8 September 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, will issue its interim results for the six-month period ended 30 June 2016 o...
|Dividend yield||0 %|
Equity Research (SNG)
The recent exclusive global deal with AstraZeneca, potentially worth $230m, to in-license SNG001 for the treatment of asthma is a strong validation of Synairgen’s in-vitro cell-based approach using...
Latest discussion posts More
“-33% seems a massive overreaction to me. Ok it is not good news, but it is not as if they have scrapped the project. I will watch, wait and hold. Best, OP.”▼
“View from finn (I have no comment to add): Synairgen has announced this morning that AstraZeneca has decided to stop the Phase IIa trial for AZD9412 due to an unusually ...”▼
“... and the higher the better!!”▼
Codes & Symbols
|Symbols||SNG, LSE:SNG, SNG.L, SNG:LN, LON:SNG, XLON:SNG|